Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD.

J Clin Oncol. 2002 Sep 1;20(17):3586-91.

PMID:
12202658
2.

Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.

Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED.

Anticancer Drugs. 2005 Apr;16(4):461-6.

PMID:
15746584
3.

Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.

Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A.

Anticancer Drugs. 2006 Nov;17(10):1223-5.

PMID:
17075323
4.

Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.

Lemm D, Muegge LO, Hoeffken K, Aklan T, Mentzel T, Thorwarth M, Schultze-Mosgau S.

Oral Maxillofac Surg. 2008 Dec;12(4):209-13. doi: 10.1007/s10006-008-0130-8.

PMID:
18751744
5.

Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.

Wang C, Luo Z, Chen J, Zheng B, Zhang R, Chen Y, Shi Y.

Medicine (Baltimore). 2015 May;94(17):e773. doi: 10.1097/MD.0000000000000773.

6.

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.

Wicherts DA, van Coevorden F, Klomp HM, van Huizum MA, Kerst JM, Haas RL, van Boven HH, van der Hage JA.

World J Surg Oncol. 2013 Mar 8;11:59. doi: 10.1186/1477-7819-11-59.

8.

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR.

Int J Cancer. 2002 Aug 20;100(6):623-6.

9.

Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.

Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D.

Clin Cancer Res. 2014 Jan 15;20(2):499-510. doi: 10.1158/1078-0432.CCR-13-1411.

10.

[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].

Zhu JH, Li QW, Xiao WH, Sun JZ, Wang RL, Lu JY.

Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):470-2. Chinese.

PMID:
21875491
11.

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2005 Feb 1;23(4):866-73.

PMID:
15681532
12.

Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.

Kérob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu-Boue A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbe C.

Clin Cancer Res. 2010 Jun 15;16(12):3288-95. doi: 10.1158/1078-0432.CCR-09-3401.

13.

Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.

Johnson-Jahangir H, Sherman W, Ratner D.

J Natl Compr Canc Netw. 2010 Aug;8(8):881-5.

PMID:
20870634
14.

The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.

Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A.

Cancer Res. 1999 Aug 1;59(15):3719-23.

15.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group.; Southwest Oncology Group..

J Clin Oncol. 2010 Apr 1;28(10):1772-9. doi: 10.1200/JCO.2009.25.7899.

16.

Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.

Price VE, Fletcher JA, Zielenska M, Cole W, Viero S, Manson DE, Stuart M, Pappo AS.

Pediatr Blood Cancer. 2005 May;44(5):511-5.

PMID:
15503291
17.

Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.

Rutkowski P, Dębiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, Ruka W.

J Eur Acad Dermatol Venereol. 2011 Mar;25(3):264-70. doi: 10.1111/j.1468-3083.2010.03774.x.

PMID:
20569296
18.

Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.

Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y.

Br J Dermatol. 2004 Jul;151(1):235-7. Review. No abstract available.

PMID:
15270901
19.

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, Casali PG.

Int J Cancer. 2011 Oct 1;129(7):1761-72. doi: 10.1002/ijc.25826.

20.

Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.

Savoia P, Ortoncelli M, Quaglino P, Bernengo MG.

Dermatol Surg. 2006 Aug;32(8):1097-102. No abstract available.

PMID:
16918576
Items per page

Supplemental Content

Support Center